Back to top
more

Aptinyx Inc. (APTX)

(Delayed Data from NSDQ)

$3.78 USD

3.78
313,385

+0.03 (0.80%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.79 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aptinyx Inc. (APTX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 6.90% and -41.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Aptinyx (APTX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (APTX) Outperforming Other Medical Stocks This Year?

Aptinyx Inc. (APTX) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aptinyx's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Aptinyx.

Aptinyx Inc. (APTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of -3.03% and -9.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Aptinyx Inc (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Aptinyx Inc (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Momentum Stocks to Buy for May 6th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 6th

The Zacks Analyst Blog Highlights: Airgain, Trilogy Metals, Aptinyx, Veritone and Tufin Software Technologies

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Airgain, Trilogy Metals, Aptinyx, Veritone and Tufin Software Technologies

Sanghamitra Saha headshot

Small Caps Bounce Back: Buy 5 Stocks With Strong Balance Sheet

by Sanghamitra Saha

Relative underperformance compared to the large caps, a super-dovish Fed and the U.S. government's gigantic aid toward small-and-mid-cap stocks have boosted pint-sized stocks lately.

Will Aptinyx Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Aptinyx

Aptinyx Inc. (APTX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.51% and -2.96%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Aptinyx Inc. (APTX) Q4 Earnings Expected to Decline

by Zacks Equity Research

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Aptinyx Inc. (APTX) Q4 Earnings Expected to Decline

by Zacks Equity Research

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aptinyx Inc. (APTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 4.35% and 2.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Aptinyx Inc. (APTX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aptinyx's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Aptinyx.

Will Aptinyx Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Aptinyx.

Zacks Market Edge Highlights: Google, Cisco, Aptinyx, Uber and Lyft

by Zacks Equity Research

Zacks Market Edge Highlights: Google, Cisco, Aptinyx, Uber and Lyft

Tracey Ryniec headshot

How Young Investors Find the Next Google

by Tracey Ryniec

Sometimes stock ideas and trends can present themselves in unlikely places. If you're paying attention.

Aptinyx Inc. (APTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.77% and -2.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Aptinyx's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Aptinyx.

All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy

by Zacks Equity Research

Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Allergan's Depression Candidate Gets Fast Track Designation

by Zacks Equity Research

The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.